Portage Biotech Inc Quick Ratio (PRTG) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Portage Biotech Inc   (NASDAQ: PRTG)

Portage Biotech Inc 's Quick Ratio

PRTG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Portage Biotech Inc 's Cash & cash equivalent grew by 812.57 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Portage Biotech Inc 's Quick Ratio to 1.52, Quick Ratio remained below Portage Biotech Inc average.

Within Major Pharmaceutical Preparations industry 343 other companies have achieved higher Quick Ratio than Portage Biotech Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 1257 to 1374.

Explain Quick Ratio?
How much Cash & cash equivalents PRTG´s has?
What are PRTG´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PRTG Quick Ratio (Mar 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Mar 31 2024)
Q4
Y / Y Current Liabilities Change -80.75 % -0.95 % -64.44 % -53.63 % 272.8 %
Y / Y Cash & cash equivalent Change -66.79 % -98.26 % -77.08 % -84.16 % -78.47 %
Quick Ratio MRQ 1.52 0.04 0.91 0.76 0.88
PRTG's Total Ranking # 1374 # 1257 # # #
Seq. Current Liabilities Change -76.59 % 141.59 % -11.59 % -61.5 % 20.47 %
Seq. Cash & cash equivalent Change 812.57 % -89.63 % 5.63 % -66.79 % -52.32 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 344
Healthcare Sector # 590
Overall Market # 1374


Quick Ratio Statistics
High Average Low
59.62 13 0.86
(Mar 31 2018)   (Mar 31 2021)




Financial Statements
Portage Biotech Inc 's Current Liabilities $ 1 Millions Visit PRTG's Balance sheet
Portage Biotech Inc 's Cash & cash equivalent $ 2 Millions Visit PRTG's Balance sheet
Source of PRTG's Sales Visit PRTG's Sales by Geography


Cumulative Portage Biotech Inc 's Quick Ratio

PRTG's Quick Ratio for the trailling 12 Months

PRTG Quick Ratio

 (Mar 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -51.9 % -11.72 % 10.87 % 62.11 % 187.56 %
Y / Y Cash & cash equivalent TTM Growth -84.37 % -83.42 % -66.44 % -64.43 % -59.22 %
Quick Ratio TTM 0.53 0.59 1.3 1.38 1.64
Total Ranking TTM # 3332 # 652 # # #
Seq. Current Liabilities TTM Growth -31.7 % -0.31 % -19.44 % -12.31 % 25.36 %
Seq. Cash & cash equivalent TTM Growth -38.84 % -54.52 % -23.79 % -26.24 % -35.14 %

Quick ratio ranking by company, industry and sector >> Back to PRTG Financial Strength Comparisons >> Go to Compare PRTG Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PRTG's Current Liabilities to $1.10 millions, cumulative Quick Ratio to 0.53 below the PRTG average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Portage Biotech Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 652 to 3332.

Explain Quick Ratio?
How much Cash & cash equivalents PRTG´s has?
What are PRTG´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 906
Within the Market # 3332


trailing twelve months Quick Ratio Statistics
High Average Low
59.62 6.99 0.86
(Mar 31 2018)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Theravance Biopharma inc   4.15 $ 130.855  Millions$ 31.502  Millions
Rain Enhancement Technologies Holdco Inc   4.15 $ 15.273  Millions$ 3.683  Millions
Xoma Royalty Corporation  4.14 $ 90.265  Millions$ 21.802  Millions
Sellas Life Sciences Group Inc   4.14 $ 28.497  Millions$ 6.888  Millions
Arrowhead Pharmaceuticals Inc   4.13 $ 911.700  Millions$ 220.541  Millions
Vyne Therapeutics Inc   4.11 $ 50.272  Millions$ 12.228  Millions
Bridgebio Pharma Inc   4.06 $ 540.599  Millions$ 133.069  Millions
Pasithea Therapeutics Corp   4.03 $ 5.341  Millions$ 1.326  Millions
Cadrenal Therapeutics Inc  3.99 $ 7.336  Millions$ 1.840  Millions
Bioharvest Sciences Inc   3.98 $ 23.025  Millions$ 5.787  Millions
Sol gel Technologies Ltd   3.89 $ 23.999  Millions$ 6.171  Millions
Nextcure Inc   3.80 $ 21.827  Millions$ 5.740  Millions
Aquestive Therapeutics Inc   3.75 $ 68.657  Millions$ 18.298  Millions
Entrada Therapeutics Inc   3.68 $ 67.837  Millions$ 18.431  Millions
Metavia Inc   3.66 $ 11.190  Millions$ 3.054  Millions
Rafael Holdings Inc  3.66 $ 37.936  Millions$ 10.366  Millions
Enveric Biosciences Inc   3.63 $ 4.294  Millions$ 1.184  Millions
Iterum Therapeutics Plc  3.61 $ 12.652  Millions$ 3.504  Millions
Dermata Therapeutics Inc   3.59 $ 9.719  Millions$ 2.704  Millions
Scpharmaceuticals Inc   3.58 $ 57.544  Millions$ 16.058  Millions
Veru Inc   3.56 $ 20.018  Millions$ 5.619  Millions
Ligand Pharmaceuticals Incorporated  3.56 $ 208.901  Millions$ 58.683  Millions
Alumis inc   3.45 $ 208.749  Millions$ 60.450  Millions
Cyclerion Therapeutics Inc   3.41 $ 3.639  Millions$ 1.067  Millions
Revelation Biosciences Inc   3.40 $ 3.705  Millions$ 1.089  Millions
Nuvectis Pharma inc   3.36 $ 29.864  Millions$ 8.894  Millions
Precigen Inc   3.35 $ 80.242  Millions$ 23.986  Millions
Cryoport inc   3.32 $ 246.028  Millions$ 74.030  Millions
Verastem Inc   3.30 $ 117.569  Millions$ 35.619  Millions
Y mabs Therapeutics inc   3.18 $ 60.310  Millions$ 18.957  Millions

Date modified: 2026-09-08T15:11:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.